663 related articles for article (PubMed ID: 33755166)
1. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
3. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
4. Prediction of
Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
[TBL] [Abstract][Full Text] [Related]
5. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of
Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
[TBL] [Abstract][Full Text] [Related]
8. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of
Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM
Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716
[No Abstract] [Full Text] [Related]
9. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
10. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
11. Survival predictors of
Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
[TBL] [Abstract][Full Text] [Related]
12. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
14. External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.
Das S; Chauhan A; Du L; Thomas KE; Jacob A; Schad A; Jain S; Jessop A; Shah C; Eisner D; Cardin DB; Ciombor KK; Goff LW; Bradshaw M; Delbeke D; Sandler M; Ramirez RA; Berlin J
JAMA Netw Open; 2022 Jan; 5(1):e2144170. PubMed ID: 35044469
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
18. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
20. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]